ERBB2 and breast cancer: To enhance the antitumor activity of CAR T cells against CD19 positive B-ALL and Her2 positive breast cancers, we inserted CD19.BBz, CD19.BBz.PD-L1, Her2.BBz, and Her2.BBz.PD-L1 CARs into the multi-cloning site of pCDH-EF1α-MCS-CMV-copGFP vector (Figure 1A).